Printer Friendly

NEORX REPORTS BENEFITS OF LUNG CANCER IMAGING PRODUCTS AND STATUS OF CANCER THERAPY DEVELOPMENT PROGRAM

 NEORX REPORTS BENEFITS OF LUNG CANCER IMAGING PRODUCTS
 AND STATUS OF CANCER THERAPY DEVELOPMENT PROGRAM
 SEATTLE, March 31 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today presented combined results of its OncoTrac(R) Small Cell and Non- Small Cell Lung Cancer imaging agents at the Innovative Drug Development Conference in New York.
 NeoRx's phase III pivotal studies compared its OncoTrac imaging products against all four standard tests combined that are used to stage the extent of cancer in patients. Paul Abrams, M.D., J.D., NeoRx's president and CEO, reported, "OncoTrac Small Cell Cancer Imaging Kit determined the extent of disease in patients as accurately (88 percent) as all these standard tests combined. So far as we know, no trials of any other product like OncoTrac has even attempted such a rigorous comparison. OncoTrac was also the most sensitive test (85 percent) by far to detect extensive disease. Importantly, negligible allergic human anti-mouse antibody response was seen.
 "We believe our data uniquely support a first use indication of our imaging agent rather than as a follow-up when other tests are equivocal. OncoTrac Non-Small Cell cancer imaging agent appears to be as accurate as standard tests in evaluating a patient's suitability for surgery, and detects distant metastases at the same time. To our knowledge, no other lung cancer detection products have reached phase III trials," said Abrams. There are approximately 40,000 new cases of small cell and 120,000 new cases of non-small cell lung cancer reported annually in the United States.
 NeoRx also described its current cancer therapy products in clinical trials and explained the value of its recently licensed pre-targeting patent. "We have demonstrated that we can administer rhenium labeled antibodies at high doses, with no loss of rhenium from the antibody, and can effect documented responses in resistant, solid tumors with just a single dose. Multiple dose studies are currently under way and early indications suggest that greater total doses can be administered," said Abrams.
 Abrams stated that the next generation of products combined NeoRx's defined, stable chelates with the pre-targeting technology. The large antibody and small radioactive chelate are injected separately and then join at the tumor site. He said the advantage is a marked reduction in exposure of bone marrow that should improve the ratio of benefit to side effects in cancer patients. NeoRx is the exclusive licensee of the basic Stanford University patent on pre-targeting.
 NeoRx Corporation develops targeted biopharmaceutical products to detect and treat disease. The company has three cancer therapy trials in progress, has filed for marketing approval with the Food and Drug Administration for two OncoTrac cancer imaging products and has completed a phase III trial for a third. Targeted biopharmaceuticals to treat cancer, restenosis after angioplasty and autoimmune diseases are in pre-clinical testing.
 -0- 3/31/92
 /CONTACT: Paul G. Abrams, president and CEO of NeoRx, 206-286-2521; or Anthony J. Russo or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation ST: Washington IN: MTC SU:


SM-GK -- NY016 -- 3236 03/31/92 08:55 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:508
Previous Article:INTERFERON SCIENCES REPORTS 1991 OPERATING RESULTS
Next Article:ACS ENTERPRISES REPORTS RESULTS
Topics:


Related Articles
NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY
NEORX DECLARES DIVIDEND
NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS
NEORX REPORTS FIRST QUARTER 1993 RESULTS
NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT
NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
NEORX REPORTS SECOND QUARTER 1993 RESULTS
NEORX REPORTS 1994 FIRST QUARTER RESULTS
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF VERLUMA(TM), SMALL CELL LUNG CANCER IMAGING AGENT DEVELOPED BY NEORX

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters